Show simple item record

dc.contributor.authorTownsend, W.en
dc.contributor.authorJohnson, R. J.en
dc.contributor.authorPottinger, B. T.en
dc.contributor.authorCounsell, N.en
dc.contributor.authorSmith, P.en
dc.contributor.authorChadwick, H.en
dc.contributor.authorEvans, Katyen
dc.contributor.authorWickham, Carolineen
dc.contributor.authorRudin, Claudius E.en
dc.date.accessioned2016-03-30T12:31:13Zen
dc.date.available2016-03-30T12:31:13Zen
dc.date.issued2016-03-22en
dc.identifier.citationA phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. 2016 Sep;57(9):2232-4en
dc.identifier.issn1029-2403en
dc.identifier.pmid27001186en
dc.identifier.doi10.3109/10428194.2015.1133814en
dc.identifier.urihttp://hdl.handle.net/11287/604005en
dc.languageENGen
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://www.tandfonline.com/doi/full/10.3109/10428194.2015.1133814en
dc.rightsArchived with thanks to Leukemia & lymphomaen
dc.subjectWessex Classification Subject Headings::Haematologyen
dc.titleA phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.en
dc.typeLetteren
dc.identifier.journalLeukemia & lymphomaen
dc.type.versionIn press (epub ahead of print)en
dc.description.admin-noteAccepted version (12 month embargo)en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record